Additionally, SRY, via its downstream target SOX9, promotes hepatocellular carcinoma (HCC) progression by upregulating CXCL5 expression and activating the CXCL5/CXCR2 signaling axis, thereby enhancing tumor cell proliferation and invasion. Here, CXCR2 is linked to hepatocellular carcinoma.